echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > [Yao Kejun] the first quarter of 2018 Lilly's performance reported that the performance of these drugs was strong, insulin glargine, englejin, dulaglutide, verzenio

    [Yao Kejun] the first quarter of 2018 Lilly's performance reported that the performance of these drugs was strong, insulin glargine, englejin, dulaglutide, verzenio

    • Last Update: 2018-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In the first quarter of 2018, Lilly's performance report showed the company's global revenue of $5.7 billion, an increase of 9% compared with the first quarter of 2017 Gross margin increased by 6% in the first quarter of 2018 compared with the first quarter of 2017, reaching US $4.129 billion Gross profit margin accounted for 72.4% of revenue, down 1.8 percentage points from the first quarter of 2017 Mr David ricks, chairman and chief executive officer of Lilly global, said: "driven by the growth of new product revenue and continuous productivity improvement, Lilly achieved very good financial performance in the first quarter, with strong revenue growth and continuous financial forecast for the whole year We are in the early stage of the new growth era, which is driven by the strong momentum of new product sales, the continuous improvement of profit margin and the in-depth layout of new product research and development Lilly will continue to bring more innovation to patients and create more value for stakeholders " Revenue growth in the United States in the first quarter was 8% to $3.155 billion, thanks to Lilly's key products, including increased sales of new products such as trulicity ®, basaglar ®, jardiance ®, verzenio and taltz, as well as increased prices of major products such as Cialis ®, Humalog ®, Strattera ®, basaglar and company animal products Revenue outside the U.S grew 11% to $2.545 billion, mainly due to the favorable impact of foreign exchange rates and the increase in new drug products including trulicity, olumiant ®, taltz, jardiance and lartruvotm In the first quarter of 2018, global Humalog revenue increased by 12% compared with the first quarter of 2017, reaching $791.7 million Revenue in the U.S increased 12% to $504.1 million, while revenue outside the U.S increased 11% to $287.6 million, less affected by the favorable impact of foreign exchange rates and the increase in sales Alimta (pemetrexed) generated $499.6 million in global revenue in the first quarter of 2018, an increase of 2% compared with the first quarter of 2017 Alimta's revenue grew 8% to US $245.3 million, mainly due to sales growth However, driven by competitive pressures and exclusive losses in some countries, Alimta revenue outside the United States fell 3% to $254.3 million, partially offsetting the positive impact of foreign exchange rates In the first quarter of 2018, global Cialis revenue dropped 7% to US $495.4 million In the first quarter of the United States, Cialis revenue was $313.4 million, up 6% from the first quarter of 2017 However, Cialis revenue outside the US decreased by 23% to US $182 million, making the overall sales trend down In the first quarter of Humulin (recombinant human insulin), global Humulin revenue increased by 4% compared with the first quarter of 2017, reaching US $325.9 million Revenue in the US rose 8% to $221.6 million Revenue outside the U.S fell 4% to $104.3 million, mainly due to lower prices in the Chinese market Forteo's global revenue in the first quarter of 2018 was $313.2 million, down 10% from the first quarter of 2017 Us revenue fell 31% to $122.1 million, mainly due to a decrease in the number of wholesale and retail purchase models and lower market prices Revenue outside the US rose 13% to $191.1 million, driven by the favorable exchange rate and higher sales Product performance since 2014 trulicity (dulaglutide) global trulicity revenue in the first quarter of 2018 was $678.3 million, an increase of 82% compared with the first quarter of 2017 U.S revenue increased 78% to $528.2 million, mainly due to increased GLP-1 demand, resulting in an increase in trulicity's market share Revenue outside the US was $151.0 million, up 96%, driven mainly by increased sales and the positive impact of the exchange rate In the first quarter of 2018, cyramza's global revenue was $183.6 million, up 7% from the first quarter of 2017 Revenue in the U.S was $68.3 million, up 3%, driven by higher sales and higher prices Revenue outside the US was $115.3 million, up 10%, driven by the positive impact of increased exchange rates and sales In the first quarter of 2018, basaglar's global revenue was $166 million Revenue in the US was $126.7 million, an increase of $12.3 million compared to the fourth quarter of 2017 Revenue outside the US is $39 million In the first quarter of 2018, jardiance's global revenue was US $151.1 million, an increase of 104% compared with the first quarter of 2017 U.S revenue grew 99% to $95 million, thanks to increased social demand for sglt-2 inhibitors, which increased jardiance's market share Revenue outside the US was $56 million, up 113% year-on-year, mainly driven by favorable exchange rates and increased sales Jardiance is jointly developed by Lilly and Boehringer Ingelheim, and the report of Lilly is only a part of jardiance's gross profit In the first quarter of 2018, taxz generated $146 million in global revenue Us operating revenue was $112.1 million, a decrease of $31.3 million compared to the fourth quarter of 2017, due to a decline in sales due to the pharmacy purchase model, even partially offset by increased demand, including the start of new patients As a result of the continued increase in new issuance, U.S foreign revenue was $35.3 million, an increase of $5.3 million compared to the fourth quarter of 2017 Lartruvo (olaratumab) generated $64.4 million in global revenue for the first quarter of 2018 Us revenue was $43 million, an increase of $1.5 million compared to the fourth quarter of 2017 Revenue outside the US was $21.4 million, an increase of $3.9 million compared to the fourth quarter of 2017 Olumiant (barictinib) generated $32.2 million in global revenue in the first quarter of 2018, an increase of $9.2 million compared with the fourth quarter of 2017, thanks to strong growth in the German market Verzenio (abemaciclib) verzenio is a treatment drug for HR +, HER2 - women with advanced breast cancer In the first quarter of 2018, the U.S revenue was $29.7 million, an increase of $8.7 million compared with the fourth quarter of 2017 In the first quarter of 2018, global AnimalHealth revenue totaled $761.3 million, down 1% from the first quarter of 2017 Global food animal revenue fell 7% to $474.3 million, driven mainly by market access pressures Global companionanima revenue increased by 10% to US $287 million, mainly due to the rising prices of several products and a small amount of favorable exchange rate The supervision of important events in Lilly in the past three months comes a day after the arthritis Advisory Committee of the US Food and Drug Administration (FDA) reassessed barictinib Barictinib, a daily oral drug, is used to treat moderate to severe active rheumatoid arthritis The committee recommends approval of 2 mg barictinib Although the committee unanimously supports the efficacy of 4 mg barictinib, it does not recommend approval of 4 mg based on safety considerations Professionals say that if barictinib is approved to go public in the US this year, its market profits will be incalculable Recently, the third indication of verzenio was approved by FDA Verzenio TM (abemaciclib) and aromatase inhibitor were used as the initial endocrine therapy to treat postmenopausal hormone receptor positive (HR +, human epidermal growth factor receptor 2 negative (HER2 -) advanced or metastatic breast cancer The phase III clinical data of cyramza ® (ramucirumab), a clinical Lilly product, used in the treatment of liver cancer is gratifying The company announced cyramza's third phase of research as a single drug for second-line treatment of HCC, also known as liver cancer The trial was in line with its primary end point of overall survival, and the company intends to launch an application in mid-2018 Lilly product taltz ® (ixekizumab) for the treatment of ankylosing spondylitis (as) phase III clinical data is gratifying, in the phase III study in line with the primary and all key secondary endpoints The company plans to submit data later this year for regulatory approval Business development Lilly is working globally with sigilon therapeutics to develop cell therapies for potential treatment of type 1 diabetes According to the terms of the agreement, Lilly will obtain the exclusive global license of afibromer technology from sigilon Sigilon will receive an advance payment of US $63 million Source of information and data: Lilly official website
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.